BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:PEP07 readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of PEP07\, from ClinicalTrials.gov estimates
 .
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT05659732-2987@assetmemo.bio
DTSTAMP:20261121T005400Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:PEP07: Phase 1 readout est. (NCT05659732)
DESCRIPTION:PEP07\, phase 1\, Acute Myeloid Leukemia.\nStudy: A Study of PE
 P07 (Checkpoint Kinase 1 Inhibitor) in Patients With Advanced Cancer\nEsti
 mated primary completion: 31 December 2026. This is a ClinicalTrials.gov e
 stimate\, not a confirmed readout date\, and it can move.\nDrug page: http
 s://assetmemo.bio/drug/pep07#upcoming-events\nRegistry record: https://cli
 nicaltrials.gov/study/NCT05659732
URL:https://assetmemo.bio/drug/pep07#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05983523-2987@assetmemo.bio
DTSTAMP:20261121T005400Z
DTSTART;VALUE=DATE:20270225
DTEND;VALUE=DATE:20270226
SUMMARY:PEP07: Phase 1 readout est. (NCT05983523)
DESCRIPTION:PEP07\, phase 1.\nStudy: A Study of PEP07 (Checkpoint Kinase 1 
 Inhibitor) in Patients with Advanced or Metastatic Solid Tumors\nEstimated
  primary completion: 25 February 2027. This is a ClinicalTrials.gov estima
 te\, not a confirmed readout date\, and it can move.\nDrug page: https://a
 ssetmemo.bio/drug/pep07#upcoming-events\nRegistry record: https://clinical
 trials.gov/study/NCT05983523
URL:https://assetmemo.bio/drug/pep07#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
